Psychiatr. pro Praxi, 2005; 4: 192-194

ANXIOLYTICS AND THEIR MECHANISM OF ACTION

MUDr. Martin Votava Ph.D, Mgr. Viktoria Agová, prof. MUDr. Miloslav Kršiak DrSc
Ústav farmakologie 3. LF UK, Praha

Anxiety diseases are one of the most frequent psychic disorders. Drugs, which are currently used, act mainly on GABAergic (benzodiazepines) or serotonergic (antidepressants) systems. This review summarizes the main mechanisms of action of anxiolytics and shows other possible options of anxiety treatment. The current therapy of anxiety is non-specific and thus researchers are still finding other neuromediator systems to influence. The most promising systems in the development of new anxiolytics are noradrenergic system, corticotropin-releasing factor receptors, neurokinin, cholecystokinin or glutamatergic NMDA receptors.

Keywords: Key words: anxiety, anxiolytics, benzodiazepines, SSRI.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Votava M, Agová V, Kršiak M. ANXIOLYTICS AND THEIR MECHANISM OF ACTION. Psychiatr. praxi. 2005;9(4):192-194.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J.Endocrinol. 160: 1-12. Go to original source... Go to PubMed...
    2. Bitran D, Shiekh M, McLeod M (1995) Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABA (A) receptors. J.Neuroendocrinol. 7: 171-177. Go to original source... Go to PubMed...
    3. Borisenko SA, Meng QH, Rauhala P, Mannisto PT (1996) Neurochemical mediators of anxiety have inconsistent effects on hypothalamic self-stimulation in rats. Pharmacol.Toxicol. 78: 354-360. Go to original source... Go to PubMed...
    4. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163: 121-141. Go to original source... Go to PubMed...
    5. Cryan JF, Kaupmann K (2005) Don't worry, B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol.Sci. 26: 36-43. Go to original source... Go to PubMed...
    6. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R (2002) Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416: 396-400. Go to original source... Go to PubMed...
    7. Johnstone TB, Hogenkamp DJ, Coyne L, Su J, Halliwell RF, Tran MB, Yoshimura RF, Li WY, Wang J, Gee KW (2004) Modifying quinolone antibiotics yields new anxiolytics. Nat.Med. 10: 31-32. Go to original source... Go to PubMed...
    8. Korpi ER, Grunder G, Luddens H (2002) Drug interactions at GABA(A) receptors. Prog.Neurobiol. 67: 113-159. Go to original source... Go to PubMed...
    9. Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, Fritschy JM, Rulicke T, Bluethmann H, Mohler H, Rudolph U (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290: 131-134. Go to original source... Go to PubMed...
    10. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, Cook G, Ferris P, Garrett L, Bristow L, Marshall G, Macaulay A, Brown N, Howell O, Moore KW, Carling RW, Street LJ, Castro JL, Ragan CI, Dawson GR, Whiting PJ (2000) Sedative but not anxiolytic properties of benzodiazepines ave mediated by the GABA(A) receptor alpha(1) subtype. Nature Neuroscience 3: 587-592. Go to original source... Go to PubMed...
    11. Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J.Nutr. 130: 1007S-1015S. Go to original source... Go to PubMed...
    12. Nutt DJ, Malizia AL (2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br.J.Psychiatry 179: 390-396. Go to original source... Go to PubMed...
    13. Olivier B, van Wijngaarden I, Soudijn W (2000) 5-HT3 receptor antagonists and anxiety; a preclinical and clinical review. European Neuropsychopharmacology 10: 77-95. Go to original source... Go to PubMed...
    14. Redmond DE, Jr., Huang YH (1979) Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci. 25: 2149-2162. Go to original source... Go to PubMed...
    15. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, Heath MJ (2001) Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl.Acad.Sci.U.S.A 98: 1912-1917. Go to original source...
    16. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809. Go to original source... Go to PubMed...
    17. Szabo ST, de Montigny C, Blier P (2000) Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int.J.Neuropsychopharmacol. 3: 1-11. Go to original source... Go to PubMed...
    18. Tornatzky W, Miczek KA (1994) Behavioral and autonomic responses to intermittent social stress: differential protection by clonidine and metoprolol. Psychopharmacology (Berl) 116: 346-356. Go to original source... Go to PubMed...
    19. Uhlirova L, Sustkova-Fiserova M, Krsiak M (2004) Behavioral effects of flumazenil in the social conflict test in mice. Psychopharmacology (Berl) 171: 259-269. Go to original source... Go to PubMed...
    20. van Megen HJ, Westenberg HG, den Boer JA, Kahn RS (1996) Cholecystokinin in anxiety. Eur.Neuropsychopharmacol. 6: 263-280. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.